FINANCIERE DE TUBIZE (TUB.BR) Stock Price, Forecast & Analysis
Europe - EBR:TUB - BE0003823409 - Common Stock
TUB.BR Key Statistics, Chart & Performance
The current stock price of TUB.BR is 203 EUR. In the past month the price decreased by -13.15%. In the past year, price increased by 36.7%.
TUB.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 43.02 | 779.32B | ||
| LLY.DE | ELI LILLY & CO | 42.45 | 768.90B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.44 | 439.19B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 18.04 | 392.27B | ||
| JNJ.DE | JOHNSON & JOHNSON | 17.85 | 388.18B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.05 | 240.19B | ||
| 1SAN.MI | SANOFI | 11.48 | 212.63B | ||
| NOT.DE | NOVARTIS AG-REG | 14.02 | 210.93B | ||
| SAN.PA | SANOFI | 11.28 | 208.98B | ||
| SNW.DE | SANOFI | 11.19 | 207.30B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 13.77 | 207.14B | ||
| 1MRKX.MI | MERCK & CO. INC. | 10.94 | 183.09B |
Related stock screener links
About TUB.BR
Company Profile
Financiere de Tubize SA is a holding company, which engages in investing in the biopharmaceuticals industry. The company is headquartered in Brussels, Bruxelles-Capitale. The firm holds minor capital in UCB SA. UCB is a Belgian pharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. UCB, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. The firm promotes the development of a sustainable biopharma ecosystem in Belgium and possibly in other geographic areas relevant to UCB.
Company Info
FINANCIERE DE TUBIZE
Allee de la Recherche, 60
Brussels BRUXELLES-CAPITALE BE
Employees: 3
Phone: 320497515208
FINANCIERE DE TUBIZE / TUB.BR FAQ
What does TUB do?
Financiere de Tubize SA is a holding company, which engages in investing in the biopharmaceuticals industry. The company is headquartered in Brussels, Bruxelles-Capitale. The firm holds minor capital in UCB SA. UCB is a Belgian pharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. UCB, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. The firm promotes the development of a sustainable biopharma ecosystem in Belgium and possibly in other geographic areas relevant to UCB.
What is the current price of TUB stock?
The current stock price of TUB.BR is 203 EUR. The price increased by 0.74% in the last trading session.
Does FINANCIERE DE TUBIZE pay dividends?
FINANCIERE DE TUBIZE (TUB.BR) has a dividend yield of 0.33%. The yearly dividend amount is currently 0.97.
What is the ChartMill rating of FINANCIERE DE TUBIZE stock?
TUB.BR has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is TUB.BR stock listed?
TUB.BR stock is listed on the Euronext Brussels exchange.
Would investing in FINANCIERE DE TUBIZE be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TUB.BR.
What is FINANCIERE DE TUBIZE worth?
FINANCIERE DE TUBIZE (TUB.BR) has a market capitalization of 9.04B EUR. This makes TUB.BR a Mid Cap stock.
TUB.BR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TUB.BR. When comparing the yearly performance of all stocks, TUB.BR is one of the better performing stocks in the market, outperforming 92.91% of all stocks.
TUB.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TUB.BR. No worries on liquidiy or solvency for TUB.BR as it has an excellent financial health rating, but there are worries on the profitability.
TUB.BR Financial Highlights
Over the last trailing twelve months TUB.BR reported a non-GAAP Earnings per Share(EPS) of 2.08. The EPS increased by 3.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 4.79% | ||
| ROE | 4.79% | ||
| Debt/Equity | 0 |
TUB.BR Forecast & Estimates
6 analysts have analysed TUB.BR and the average price target is 235.11 EUR. This implies a price increase of 15.82% is expected in the next year compared to the current price of 203.